Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Kyttaro logo

Launched in Q2 2021 as an affiliate of Cambridge Science (CSC), Kyttaro is a pure-play biotech company that plans to develop innovative biologics to treat ASCVD and related metabolic and inflammatory conditions.


Cardiovascular disease, the world’s leading cause of death, has been underinvested by the biopharmaceutical industry for decades. The recent discovery of novel genetically validated Atherosclerotic Cardiovascular disease (ASCVD) targets, new therapeutic modalities and the pivotal CANTOS trial, which established the efficacy of anti-inflammatory therapy in ASCVD, has the therapeutic class on the precipice of a new era in research and development. Despite aggressive glycemic and LDL-C control, primarily through incretins and statin therapeutics, there remains a significant unmet need for high-risk ASCVD patients.

Kyttaro’s clinical strategy focuses on rare and severe diseases associated with ASCVD risk factors related to TG and cholesterol levels and inflammation to establish safety and efficacy and ensure early market access and commercial success. Once Kyttaro establishes the efficacy of the assets in these rare and severe disorders, the company plans to enter the much larger ASCVD market through pharma partnerships.


The company has an ongoing collaboration with Professor Shoumo Bhattacharya, Professor of Translational Medicine at the University of Oxford’s Radcliffe Department of Medicine, in which an anti-inflammatory peptide technology platform is being developed. The company plans to complement the anti-inflammatory peptide technology platform with multiple advanced first-in-class biologics that lower TGs and/or improve cholesterol levels to reduce ASCVD.



We are pleased to be joining the flourishing Oxford University bioscience community. The sense of excitement and momentum is palatable. With record resources being committed on the ground and in the lab, against a backdrop of world-class science, the scene reminds me of Kendall Square a few years back. Kyttaro is looking forward to contributing to the critically important acceleration of translational research, which will lead to novel therapeutics treating patients suffering from the disease
- Douglas Eby, Kyttaro Founder and CEO


 Kyttaro's website